Use of ASMase Antagonists to Protect the Ovaries from Damage Caused by Chemotherapy, Radiation or the Effects of Aging

SK 896

Summary of Invention

Ceramide, which mediates stress-induced apoptosis, is generated from sphingomyelin in a reaction catalyzed by acid sphingomyelinase (ASMase). Antagonists of ASMase, which prevent generation of ceramide and thereby prevent stress-induced apoptosis, can be used to protect the ovary from the apoptotic cell death otherwise induced by chemotherapy, radiotherapy or the effects of aging.

Drs. Richard N. Kolesnick and Jonathan L. Tilly have demonstrated that administration of lysophospholipids that antagonize ASMase function, including sphingolipids and, more specifically, sphingosine 1-phosphate (S1P) and S1P analogs, protects the female germline from normal aging as well as from the premature failure resulting from cancer therapy regimens, including chemotherapy or radiotherapy. Administration of a composition containing S1P or an S1P analog provides a new approach to the preservation of ovarian function and could be useful in preventing infertility in female cancer patients, in preventing or ameliorating menopausal syndromes, and in improving in vitro fertilization techniques.

Advantages

There are no similar therapies presently available.

Areas of Application

Therapeutic

Stage of Development

Proof of concept established in mice

Lead Inventor

Richard Kolesnick, MD, Laboratory Head, Molecular Pharmacology & Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering

Patent Information

References

Contact Information

Zhenyan Yan, PhD
Licensing Manager
Tel: 646-888-1081
Stage of Development
Animal studies
Technology Types